ArticleScientific reports2025
Systemic PCSK9 elevation characterises autoimmune liver disease across sexes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum cholesterol. Its expression is particularly abundant in hepatocytes, yet its role in autoimmune liver diseases remains unclear. Here we investigated serum PCSK9 levels in patients with autoimmune liver diseases and compared them to healthy controls, with attention to sex-specific differences. Serum PCSK9 levels were measured in 100 patients with autoimmune liver diseases - 57 with primary sclerosing cholangitis (PSC), 33 with primary biliary cholangitis (PBC), and 10 with autoimmune hepatitis (AIH)-and 88 healthy controls. Subgroup analyses were conducted based on sex and disease type. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. PCSK9 levels were significantly elevated in patients with autoimmune liver diseases compared to healthy controls (p < 0.001). In male patients, serum PCSK9 levels discriminated between patients with PSC and controls. In female patients, they discriminated between patients with PBC and controls. The area under the ROC curve (AUROC) for distinguishing between these groups was 0.765 ± 0.057 and 0.834 ± 0.047, respectively. Patients with almost normal aminotransferase and cholestasis marker levels (n = 47) had significantly higher PCSK9 levels than controls. The AUROC was 0.788 ± 0.039 and a serum PCSK9 level of 224 ng/ml had a sensitivity of 92% and a specificity of 60% for diagnosing autoimmune liver disease. Serum PCSK9 levels did mostly not correlate with serum cholesterol, markers of liver disease severity, the model for end stage liver disease score, or fibrosis stage. Patients who experienced decompensation or required a liver transplant during the course of their disease had PCSK9 levels similar to those who did not experience these adverse events. Serum PCSK9 levels are elevated in both male and female patients with autoimmune liver diseases, independent of cholesterol levels or fibrosis stage. PCSK9 may serve as a biomarker in the diagnosis of autoimmune liver disease, even in patients with almost normal liver function test results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.